RVTY
Revvity, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -3.7% ·
net new positions +6.2%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | +9 | 65.85M | $7.33B | +14 | −6 |
| Q1 2026 | 126 | -7 | 72.99M | $6.39B | +4 | −12 |
| Q4 2025 | 133 | 0 | 75.39M | $7.30B | +3 | −2 |
| Q3 2025 | 19 | +1 | 44.69M | $3.92B | +1 | −1 |
| Q2 2025 | 16 | +1 | 42.02M | $4.06B | +3 | −2 |
| Q1 2025 | 12 | -1 | 20.50M | $2.17B | — | −1 |
| Q4 2024 | 13 | 0 | 18.11M | $2.02B | +1 | −1 |
| Q3 2024 | 12 | -1 | 11.86M | $1.51B | +1 | −2 |
| Q2 2024 | 13 | — | 11.86M | $1.24B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 14.09M | — | $1.36B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 8.86M | — | $856.49M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | T. Rowe Price ✦ | 7.98M | -16.6% | $771.64M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 5.02M | -2.9% | $485.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.98M | -0.6% | $286.51M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | PRIMECAP Management ✦ | 1.36M | +18.7% | $131.50M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 1.29M | +3.7% | $124.57M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 209.43K | — | $20.26M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | Gotham Asset Management ✦ | 100.06K | -7.7% | $9.68M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 48.29K | New | $4.67M | 0.0% | New | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 28.89K | -58.4% | $2.79M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 23.20K | +2.9% | $2.24M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 16.67K | +97.3% | $1.61M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 14 | Fisher Asset Management ✦ | 15.56K | -74.9% | $1.51M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 12.88K | New | $1.25M | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 2.60K | New | $251,762 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $4.67M | 0.0% |
| Citadel Advisors | $1.25M | 0.0% |
| Two Sigma Investments | $251,762 | 0.0% |
Exited
| Adage Capital Partners | $11.75M | was 0.0% |
| Marshall Wace | $308,936 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 495 holders, 115.11M shares, $7.19B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.63K sh · $235,728
Officer · 7.33K sh · $1.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology